Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1)

Stem Cells

Volumn 25, Issue 1, 2007, Pages 165-173

  Guglielmelli, Paola ^a   Zini, Roberta ^b   Bogani, Costanza ^a   Salati, Simona ^b   Pancrazzi, Alessandro ^a   Bianchi, Elisa ^b   Mannelli, Francesco ^a   Ferrari, Sergio ^b   Le Bousse Kerdilès, Marie Caroline ^c   Bosi, Alberto ^a   Barosi, Giovanni ^d   Migliaccio, Anna Rita ^e,f   Manfredini, Rossella ^b   Vannucchi, Alessandro M ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c INSERM   (France)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^e ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^f UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

CD34+ cells; Gene expression profiling; Idiopathic myelofibrosis; JAK2V617F mutation; WT1

Indexed keywords

CD164 ANTIGEN; CD9 ANTIGEN; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; HIGH MOBILITY GROUP A2 PROTEIN; JANUS KINASE 2; TRANSCRIPTOME; UVOMORULIN; WT1 PROTEIN;

ADULT; AGED; ARTICLE; CD34 SELECTION; CELL DIFFERENTIATION; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC ASSOCIATION; GENETIC REGULATION; GRANULOCYTE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MYELOID METAPLASIA; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; STEM CELL; THROMBOCYTE COUNT; THROMBOCYTHEMIA; TRANSCRIPTOMICS;

ALGORITHMS; ANTIGENS, CD34; DNA MUTATIONAL ANALYSIS; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REARRANGEMENT; GENES, ABL; GENES, WILMS TUMOR; HEMATOPOIETIC STEM CELLS; HUMANS; MYELOFIBROSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PLURIPOTENT STEM CELLS; POLYMERASE CHAIN REACTION; RNA;

EID: 33845982875     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.2006-0351     Document Type: Article

References (55)

1. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-2302.
2. Barosi G. Myelofibrosis with myeloid metaplasia: Diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol 1999;17:2954-2970.
3. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med 2000;342:1255-1265.
4. Xu M, Bruno E, Chao J et al. The constitutive mobilization of bone marrow-repopulating cells into the peripheral blood in idiopathic myelofibrosis. Blood 2005;105:1699-1705.
5. + cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases. Blood 2005;105:4508-4515.
6. Barosi G, Viarengo G, Pecci A et al. Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia. Blood 2001;98:3249-3255.
7. Arora B, Sirhan S, Hoyer JD et al. Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: A prospective evaluation of prognostic value in 94 patients. Br J Haematol 2005;128:42-48.
8. Mesa RA, Li CY, Ketterling RP et al. Leukemic transformation in myelofibrosis with myeloid metaplasia: A single-institution experience with 91 cases. Blood 2005;105:973-977.
9. Castro-Malaspina H, Jhanwar SC. Properties of myelofibrosis-derived fibroblasts. Prog Clin Biol Res 1984;154:307-322.
10. Le Bousse-Kerdiles MC, Martyre MC. Involvement of the fibrogenic cytokines, TGF-beta and bFGF, in the pathogenesis of idiopathic myelofibrosis. Pathol Biol (Paris) 2001;49:153-157.
11. Villeval JL, Cohen-Solal K, Tulliez M et al. High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood 1997;90:4369-4383.
12. Yan XQ, Lacey D, Hill D et al. A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): Reversal of disease by bone marrow transplantation. Blood 1996;88:402-409.
13. Vannucchi AM, Bianchi L, Cellai C et al. Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low) mice). Blood 2002;100:1123-1132.
14. Pikman Y, Lee BH, Mercher T et al. MPLW515L Is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006;3:e270.
15. Vannucchi AM, Pancrazzi A, Guglielmelli P et al. Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis. Am J Pathol 2005;167:849-858.
16. Levine RL, Wadleigh M, Cools J et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-397.
17. Baxter EJ, Scott LM, Campbell PJ et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-1061.
18. James C, Ugo V, Le Couedic JP et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-1148.
19. Kralovics R, Passamonti F, Buser AS et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-1790.
20. Lippert E, Boissinot M, Kralovics R et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood 2006;108:1865-1867.
21. Antonioli E, Guglielmelli P, Pancrazzi A et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 2005;19:1847-1849.
22. Lacout C, Pisani DF, Tulliez M et al. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006;108:1652-1660.
23. Wernig G, Mercher T, Okabe R et al. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006;107:4274-4281.
24. Cazzola M, Skoda R. Gain of function, loss of control - a molecular basis for chronic myeloproliferative disorders. Haematologica 2005;90:871-874.
25. Kaushansky K. On the molecular origins of the chronic myeloproliferative disorders: It all makes sense. Blood 2005;105:4187-4190.
26. Ebert BL, Golub TR. Genomic approaches to hematologic malignancies. Blood 2004;104:923-932.
27. low cells reflect the persistence of normal primitive hematopoietic progenitors in myeloid metaplasia with myelofibrosis? Blood 2003;102:1551-1552.
28. Barosi G, Ambrosetti A, Finelli C et al. The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. Br J Haematol 1999;104:730-737.
29. Dupriez B, Morel P, Demory JL et al. Prognostic factors in agnogenic myeloid metaplasia: A report on 195 cases with a new scoring system. Blood 1996;88:1013-1018.
30. Marchetti M, Barosi G, Balestri F et al. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: A phase II trial. J Clin Oncol 2004;22:424-431.
31. + cell counts based on the ISHAGE guidelines. International Society of Hematotherapy and Graft Engineering. Cytometry 1998;34:61-70.
32. Manfredini R, Zini R, Salati S et al. The kinetic status of hematopoietic stem cell subpopulations underlies a differential expression of genes involved in self-renewal, commitment, and engraftment. STEM CELLS 2005;23:496-506.
33. Boucheix C, Rubinstein E. Tetraspanins. Cell Mol Life Sci. 2001;58:1189-1205.
34. Zannettino AC, Buhring HJ, Niutta S et al. The sialomucin CD164 (MGC-24v) is an adhesive glycoprotein expressed by human hematopoietic progenitors and bone marrow stromal cells that serves as a potent negative regulator of hematopoiesis. Blood 1998;92:2613-2628.
35. Burger JA, Kipps TJ. CXCR4: A key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006;107:1761-1767.
36. + hematopoietic stem cells. Blood 2002;99:2037-2044.
37. Clay D, Rubinstein E, Mishal Z et al. CD9 and megakaryocyte differentiation. Blood 2001;97:1982-1989.
38. + hematopoietic stem cells from patients with agnogenic myeloid metaplasia using oligonucleotide microarrays. STEM CELLS 2005;23:631-637.
39. Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 2004;303:1483-1487.
40. Falanga A, Marchetti M, Barbui T et al. Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: The role of neutrophils. Semin Hematol 2005;42:239-247.
41. Gene Expression Omnibus profiles. Available at http://www.ncbi.nlm.nih. gov/geo, GDS781. Accessed October 4, 2005.
42. Tefferi A, Sirhan S, Lasho TL et al. Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia. Br J Haematol 2005;131:166-171.
43. Goerttler PS, Steimle C, Marz E et al. The Jak2V617F mutation, PRV-1 overexpression and EEC formation define a similar cohort of MPD patients. Blood 2005;106:2862-2864.
44. Kralovics R, Teo SS, Buser AS et al. Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood 2005;106:3374-3376.
45. Keilholz U, Menssen HD, Gaiger A et al. Wilms' tumour gene 1 (WT1) in human neoplasia. Leukemia 2005;19:1318-1323.
46. Cilloni D, Gottardi E, Messa F et al. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. J Clin Oncol 2003;21:1988-1995.
47. Inoue K, Sugiyama H, Ogawa H et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994;84:3071-3079.
48. Inoue K, Tamaki H, Ogawa H et al. Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells. Blood 1998;91:2969-2976.
49. Tsuboi A, Oka Y, Ogawa H et al. Constitutive expression of the Wilms' tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF). Leuk Res 1999;23:499-505.
50. Jomgeow T, Oji Y, Tsuji N et al. Wilms' tumor gene WT1 17AA(-)/KTS(-) isoform induces morphological changes and promotes cell migration and invasion in vitro. Cancer Sci 2006;97:259-270.
51. Sakajiri S, O'Kelly J, Yin D et al. Dlk1 in normal and abnormal hematopoiesis. Leukemia 2005;19:1404-1410.
52. Miyazato A, Ueno S, Ohmine K et al. Identification of myelodysplastic syndrome-specific genes by DNA microarray analysis with purified hematopoietic stem cell fraction. Blood 2001;98:422-427.
53. Huang CC, Chuang JH, Huang LL et al. The human Delta-like 1 homologue is implicated in the progression of liver fibrosis in biliary atresia. J Pathol 2004;202:172-179.
54. Oka Y, Tsuboi A, Taguchi T et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A 2004;101:13885-13890.
55. Barosi G, Bordessoule D, Briere J et al. Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET). Blood 2005;106:2849-2853.